Analyst consensus rating
LifeStance Health Group Analyst Rating: Buy
Direct answer
LifeStance Health Group's consensus rating is Buy.
10 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $14.40.
Forecast evidence checked October 17, 2026.
Get free LifeStance Health Group email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $11.74
- Average price target
- $14.40
- High price target
- $18.00
- Low price target
- $12.00
- Low target gap
- +2.2%
- Target upside
- +22.7%
- High target gap
- +53.3%
- Target range width
- 51.1%
- Consensus rating
- Buy
- Analysts
- 10
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for LifeStance Health Group?
LifeStance Health Group has a verified Buy consensus. The same dataset has an average price target of $14.40.
How far are LifeStance Health Group's low and high targets from the recorded price?
The low target implies +2.2%, while the high target implies +53.3%.
How many analysts are included in LifeStance Health Group's consensus?
The verified consensus includes 10 analysts.
How is LifeStance Health Group's target upside or downside calculated?
The average target of $14.40 is divided by the recorded price of $11.74, then one is subtracted to produce +22.7%. This does not guarantee a future return.
When was LifeStance Health Group's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.